Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor‐risk metastatic renal cell carcinoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|19|3435-3443

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.19, 2015-10, pp. : 3435-3443

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combination of Gemcitabine and Doxorubicin in Rapidly Progressive Metastatic Renal Cell Carcinoma and/or Sarcomatoid Renal Cell Carcinoma

By  

Oncology, Vol. 80, Iss. 3-4, 2011-07 ,pp. : 214-218

Karger

Access to resources Recommend Favorite

Safety and Efficacy of Sunitinib in Patients from Italy with Metastatic Renal Cell Carcinoma: Final Results from an Expanded-Access Trial

By  

Oncology, Vol. 88, Iss. 5, 2015-01 ,pp. : 273-280

Karger

Access to resources Recommend Favorite

Continuous Therapy with Sunitinib in Patients with Metastatic Renal Cell Carcinoma

By  

Oncology Research and Treatment, Vol. 31, Iss. 8-9, 2008-07 ,pp. : 485-485

Karger

Access to resources Recommend Favorite

Phase II Study with Interferon alpha-2a and 13-cis-Retinoic Acid in Patients with Metastatic Renal Cell Carcinoma. A Trial of the Phase II Study Group of the Association for Medical Oncology of the German Cancer Society

By  

Oncology Research and Treatment, Vol. 22, Iss. 5, 1999-11 ,pp. : 412-415

Karger

Access to resources Recommend Favorite

Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 919-8172, Iss. 10, 2015-10 ,pp. : 888-897

John Wiley & Sons Inc

Access to resources Recommend Favorite